Trade AtaiBeckley Inc - ATAI CFD

Trading Conditions

• Type: CFD
• Spread: 0.03
• Long position overnight funding adjustment: -0.02151%
• Short position overnight funding adjustment: -0.00071%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 3.35
• Open: 3.38
• 1-Year Change: 119.48%
• Day's Range: 3.38 - 3.63

What is AtaiBeckley Inc (ATAI)?

AtaiBeckley Inc is a biotechnology company focused on the development of therapeutics for mental health disorders. The company explores novel approaches to treatment by leveraging psychedelic compounds and other innovative modalities. It operates through a network of subsidiaries and partnerships to advance research and clinical development programs. AtaiBeckley aims to address conditions such as depression, anxiety, and post-traumatic stress disorder by developing therapies that target underlying neurological mechanisms. The company is part of a growing sector within biotechnology that seeks to expand treatment options for psychiatric conditions through scientific innovation.

AtaiBeckley Inc Stock Price Today: Live Overview

The price today is shaped by current trading levels with Samsara Inc. priced at $3.56. Its daily trading range covers from $3.35 to $3.63, reflecting a price change of +5.3571%.

FAQ: AtaiBeckley Inc (ATAI)

What is the current price of ATAI stock?

The current trading price is $3.56.

Does ATAI pay dividends?

Dividends are not paid by the company.

Does ATAI have a formal corporate presence or regional headquarters in the UAE?

AtaiBeckley Inc operates in the UAE through partners and distributors and does not have an official regional office or subsidiary.

What is ATAI best known for?

The company is most famous for its development of psychedelic medicines and mental health treatments.

What assets are typically shown together with ATAI?

Commonly shown alongside ATAI: Standard BioTools Inc, UBS Group AG - US, SATS